Functionalized protein microparticles targeting hACE2 as a novel preventive strategy for SARS-CoV-2 infection

Int J Pharm. 2023 May 10:638:122921. doi: 10.1016/j.ijpharm.2023.122921. Epub 2023 Apr 5.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), resulting in a serious burden on public health and social economy worldwide. SARS-CoV-2 infection is mainly initialized in the nasopharyngeal cavity through the binding of viral spike (S) protein to human angiotensin-converting enzyme 2 (hACE2) receptors which are widely expressed in many human cells. Thus, blockade of the interaction between viral S protein and hACE2 receptor in the primary entry site is a promising prevention strategy for the management of COVID-19. Here we showed protein microparticles (PMPs) decorated with hACE2 could bind and neutralize SARS-CoV-2 S protein-expressing pseudovirus (PSV) and protect host cells from infection in vitro. In the hACE2 transgenic mouse model, administration of intranasal spray with hACE2-decorated PMPs markedly decreased the viral load of SARS-CoV-2 in the lungs though the inflammation was not attenuated significantly. Our results provided evidence for developing functionalized PMPs as a potential strategy for preventing emerging air-borne infectious pathogens, such as SARS-CoV-2 infection.

Keywords: Preventive strategy; Protein microparticles; SARS-CoV-2; hACE2.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Animals
  • COVID-19* / prevention & control
  • Humans
  • Mice
  • Mice, Transgenic
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / metabolism

Substances

  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2
  • Spike Glycoprotein, Coronavirus